Harvard Bioscience, Inc. — FY2022 Form 10-K
Business context and reporting period. The filing covers the fiscal year ended December 31, 2022, compared with FY2021. Harvard Bioscience develops, manufactures and sells life-science research and preclinical testing products and services globally. Its product families are Cellular and Molecular Technologies (CMT) and Preclinical; CMT represented about 51% of 2022 revenue and Preclinical about 49%.
Financial performance and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $113.3 million | $118.9 million |
| Gross profit / margin | $60.8 million / 53.7% | $67.7 million / 56.9% |
| Operating income (loss) | ($6.9 million) | $2.1 million |
| Net income (loss) | ($9.5 million) | ($0.3 million) |
| Basic and diluted loss per share | ($0.23) | ($0.01) |
| Cash from operating activities | $1.2 million | $1.3 million |
| Cash and cash equivalents, year-end | $4.5 million | $7.8 million |
| Credit Agreement borrowings, gross, year-end | $47.7 million | $49.5 million |
Cash used in investing activities was $1.6 million, primarily for capital expenditures; cash used in financing activities was $2.8 million. The year-end weighted-average borrowing rate was 7.6%, and unused borrowing capacity was $2.9 million. The credit facility matures in December 2025. Management said available cash, operating cash generation and debt capacity were expected to fund operations and planned expenditures for at least the next 12 months, subject to risks and forecast assumptions.
Material changes versus FY2021
- Revenue declined 4.7%, chiefly from lower Preclinical sales, weaker European revenue and an unfavorable $3.4 million currency impact. Greater China revenue increased, while Europe and the rest of the world declined; U.S. revenue was broadly flat.
- Gross margin fell 3.2 percentage points. Management cited lower revenue and reduced overhead absorption, higher labor, material and freight costs, and roughly $1.5–$1.6 million of charges tied to discontinuing non-strategic products. The filing gives slightly different amounts in different sections.
- The company moved from $2.1 million of operating income to a $6.9 million operating loss, and net loss widened to $9.5 million. Research and development expense rose 14.2% to $12.3 million, mainly for Preclinical product development; interest expense rose 65.5% to $2.5 million.
- Cash decreased by $3.3 million. Operating cash flow was slightly lower, with litigation-related payments and operating losses partly offset by improved receivable collections and payables management.
Outlook, commentary, risks and unusual items
- Management expected supply-chain disruptions, component and labor shortages, and related cost pressures to continue into 2023. Inflation, higher interest rates, foreign-exchange volatility, economic softness in Europe, the Russia-Ukraine conflict and COVID-related shutdowns in China negatively affected 2022 results.
- During 2022, the company rationalized products and reduced headcount in Europe and North America, recording severance costs. Management said the actions were intended to improve the cost structure and focus resources on growth and profitability; benefits are not assured.
- The company was out of compliance with certain credit covenants at September 30, 2022, but amended the credit agreement in November and reported compliance at December 31, 2022. The amended facility includes leverage and fixed-charge coverage tests, restrictions on additional debt and acquisitions, and lender remedies for default.
- A February 2023 interest-rate swap covering an initial $33.4 million notional amount converts the SOFR-based component to a 4.75% fixed rate through December 2025; the credit-agreement margin remains additional.
- The 2017 Biostage-related wrongful-death litigation and related claims were settled in April 2022 and dismissed with prejudice. The company received Biostage Series E preferred stock in satisfaction of $4.0 million of indemnification obligations; its year-end carrying value was $4.1 million. Biostage’s financial condition and the limited liquidity of its shares make the investment’s value uncertain and potentially subject to substantial loss. Other ordinary-course legal matters were not accrued because management did not consider losses probable and reasonably estimable.
- The independent auditor gave an unqualified opinion on the financial statements and on internal control over financial reporting. The preferred-stock valuation was identified as a critical audit matter. Management reported disclosure controls and internal control over financial reporting as effective at year-end.
- No formal numeric revenue or earnings guidance is provided in the filing. The company said it does not intend to pay cash dividends in the foreseeable future.
Important facts for investors to verify
- Whether revenue stabilizes and gross margin recovers as supply, labor and freight costs evolve and portfolio actions take effect.
- Whether operating cash generation can support debt service, capital spending and liquidity needs, given $4.5 million of year-end cash and only $2.9 million of unused borrowing capacity.
- Ongoing compliance with amended credit covenants, the impact of the 2025 maturity, and the actual interest-cost benefit of the swap.
- The recoverability and valuation of the $4.1 million Biostage preferred-stock investment, including Biostage’s need for additional capital.
- Whether management’s expected 12-month liquidity runway remains valid under continued macroeconomic, currency and supply-chain pressure.